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Background: Alzheimer’s Disease (AD) is the most widespread form of dementia in the elderly but despite
progress made in recent years towards a mechanistic understanding, there is still an urgent need for disease
modification therapy and for early diagnostic tests. Substantial international efforts are being made to discover and
validate biomarkers for AD using candidate analytes and various data-driven 'omics' approaches. Cerebrospinal fluid
is in many ways the tissue of choice for biomarkers of brain disease but is limited by patient and clinician
acceptability, and increasing attention is being paid to the search for blood-based biomarkers. The aim of this study
was to use a novel in silico approach to discover a set of candidate biomarkers for AD.
Methods: We used an in silico literature mining approach to identify potential biomarkers by creating a
summarized set of assertional metadata derived from relevant legacy information. We then assessed the validity of
this approach using direct assays of the identified biomarkers in plasma by immunodetection methods.
Results: Using this in silico approach, we identified 25 biomarker candidates, at least three of which have
subsequently been reported to be altered in blood or CSF from AD patients. Two further candidate biomarkers,
indicated from the in silico approach, were choline acetyltransferase and urokinase-type plasminogen activator
receptor. Using immunodetection, we showed that, in a large sample set, these markers are either altered in
disease or correlate with MRI markers of atrophy.
Conclusions: These data support as a proof of concept the use of data mining and in silico analyses to derive valid
biomarker candidates for AD and, by extension, for other disorders.
Keywords: Alzheimer’s disease, Proteomics, Biomarkers, Choline acetyltransferase (ChAt), Urokinase-type
plasminogen activator receptor (PLAUR), Intelligence network, Bioinformatics, MRI, in silico, Literature miningBackground
Alzheimer’s disease (AD) is one of the commonest
causes of dementia resulting in a severe loss of intellec-
tual abilities including memory. The main histological
features of AD in brain are amyloid plaques and neuro-
fibrillary tangles, due to accumulation, respectively, of
amyloid beta (Aβ) peptide and tau protein in insoluble
form. The causes of this, and other pathology found in
the AD brain, are not known with certainty but are likely
to be multifactorial. This multifactorial and only partially* Correspondence: simon.lovestone@kcl.ac.uk
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reproduction in any medium, provided the orunderstood pathogenesis complicates both drug and bio-
marker discovery.
The search for biomarkers to aid accurate diagnosis,
predict progression and for use in clinical trials has be-
come a major research goal [1,2]. The most widely used
strategy for the discovery of biomarkers is predicated on
the identification of potential candidate biomarkers
using knowledge of disease processes followed by valid-
ation, comparing healthy control to affected subjects [3].
In many respects, the optimal source of human tissue
for the investigation of AD biomarkers is cerebrospinal
fluid (CSF) and the demonstration of lowered CSF Aβ
and raised CSF tau and phosphorylated tau in AD is the
prime example of candidate biomarker discovery andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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normal elderly control design [4].
However, all three approaches - candidate discovery,
case–control design and the use of CSF have their draw-
backs. CSF although ideal in many respects as it bathes
the diseased organ, is limited by patient and clinician ac-
ceptability, especially for repeated measurements.
Affected case versus normal elderly control experimental
design is severely limited by the long prodromal phase
in AD, meaning many apparently unaffected controls
may have substantial occult pathology. Candidate bio-
markers are limited by the complex multifactorial path-
ology in AD meaning that beyond Aβ and tau it
becomes difficult to ascertain true candidates. In an ef-
fort to overcome the limitations of CSF, we, and others,
have pursued, with some early indications of success,
markers in plasma that might act as biomarkers of dis-
ease [5]. To overcome the problems of occult pathology
and to identify biomarkers of potential utility, two broad
approaches have been employed; firstly comparing
people with prodromal states, for example in mild cogni-
tive impairment (MCI) who progress to AD, to those
who do not, and secondly comparing both affected and
asymptomatic people by a non-clinical marker of disease
such as MRI measures of atrophy or PET measures of
amyloid load [6,7]. This latter approach has been
described variously as an endophenotype or extreme
phenotype design. To mitigate the limitations of the can-
didate marker approach many have used a range of data-
driven technologies including proteomic and genomic
platforms and increasingly these datasets are being
aggregated for biomarker discovery and understanding
pathogenesis; for example in renal disease where over
200 datasets are mined in a web-based application to
identify disease associated proteins [8].
Here we report a novel approach to biomarker discov-
ery through the utilization of data-driven biomarker dis-
covery in silico followed by validation in blood using
automated analysis of structural MRI as an endopheno-
type measure of disease. The in silico study started by
generating massive volumes of assertional data repre-
sented in the form of an Intelligence Network. Asser-
tions are simple factual representations of statements
made in the biomedical literature and other sources.
They can be compiled into a semantically consistent
form by applying comprehensive vocabularies and lexical
matching approaches to yield a navigable database
known as an Intelligence Network (IN). For this study,
the IN contained assertions relating to proteins
expressed in the brain and associated with pathology
relevant to AD. These are two important features for an
ideal biomarker for AD, assuming that such proteins
could be measured in readily accessible fluids such as
blood or urine. An in vitro study of two putative markersidentified by the in silico screen - Choline Acetyltrans-
ferase (ChAt) and urokinase-type Plasminogen Activator
Receptor (PLAUR) - provided evidence supporting the
validity of the method suggesting that in silico screening
for biomarkers in AD and, by extrapolation, other disor-
ders, is a productive approach.
Methods
In silico discovery of candidate biomarkers
To identify a set of candidate biomarkers for AD, we ap-
plied an informatics approach that would enable a com-
prehensive analysis of a body of information embedded
in publicly available literature sources and other infor-
mation databases relevant to AD. The approach used
resulted in the generation of thousands of highly accur-
ate semantically consistent observational facts, known as
assertions, which are represented in the form of subject-
verb-object constructs and referenced back to the ori-
ginal source(s) e.g. “Amyloid Deposition_IS ASSO-
CIATED WITH_Alzheimer’s Disease”; “BACE-1_IS
INVOLVED IN_Amyloid Formation”; “Syntax in 1_IS
EXPRESSED IN_Hippocampus”.
Behind each assertion is a rich vocabulary that renders
that assertion semantically consistent with the other
assertions of the same nature. For example, the path-
ology term Amyloid Deposition can be described within
the literature in a variety of ways as ‘abnormal depos-
ition of amyloid plaques’, ‘amyloid infiltration’, ‘amyloid
deposits’, ‘amyloid protein deposition’ etc. Amyloid De-
position is defined as the preferred ‘concept’, and all
other terms link to that concept to generate a semantic-
ally consistent IN. All concepts are defined as a Concept
Type e.g. in the case of Amyloid Deposition, a Patho-
logical Observation. The result is a comprehensive and
unbiased overview of relevant published data relating to
AD, expressed in a format that can be readily navigated,
searched and analyzed.
Scope of the intelligence network
To define the scope of the IN relevant to the identifica-
tion of candidate biomarkers of AD, we set the criteria
for the ideal biomarker. We defined that any biomarker
for AD would ideally be a protein with a known role in
the pathological development of the disease and have ex-
pression patterns within the brain that correlate with the
localized hallmarks of AD pathology. We also defined an
interest in proteins that had been reported to show pat-
terns of upregulation. We made assumptions that such
proteins could be ultimately identified in accessible
fluids such as serum or urine. Thus, the IN that was
generated linked data relating to protein/mRNA expres-
sion in relevant brain structures (e.g. hippocampus) with
relevant pathological observations (e.g. loss of memory
and tau phosphorylation). A network map of key
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this guided the build of the IN.
Assertion generation
The derivation of assertions from a body of historic in-
formation is challenging for a number of reasons. Firstly,
the vocabulary used across the medical literature is
highly varied and is typified by the use of synonyms,
abbreviations, and idiosyncratic acronyms. Secondly,
biomedical writing styles are diverse, with often complex
linguistic patterns, involving descriptive terms, extended
phrases, and statements or assertions that cross more
than one sentence. There has been much effort invested
in development of automated text mining methods that
yield both sufficiently high accuracy and good recall.
Our pragmatic approach is semi-automated i.e. auto-
mated extraction of possible subject-verb-object rela-
tionships (powered by rich vocabularies and synonym
associations) is followed by manual validation.
To enable lexical matching and to deal with the syno-
nym variations across the data sources of interest, a rich
set of pre-curated vocabularies was developed, relating
to subtypes of AD, AD-related pathological observations,
brain regions affected by AD, and proteins (and asso-
ciated genes/mRNAs). Sample vocabularies used for
Pathological Observations and Tissue are illustrated in
Table 1. The vocabularies for Protein/mRNAs are too
numerous to be listed, but comprised all known human
proteins as defined in the publicly accessible protein
database UniProt [9]. Each Concept was associated with
a comprehensive set of synonymous terms.
In addition to the use of vocabularies around Proteins,
Pathological Observations and Tissues, the assertion-
generation procedure also relied on the use of specific
verbs or relationships (again with synonyms) between
the key Concept Types. The preferred relationships forFigure 1 Network map used to guide the assertion generation for an
biomarkers for AD. Assertions could be direct links between proteins/mR
for familial forms of AD, such as OMIM record #104300), via pathological pr
tangles, hippocampal atrophy, tau deposition), or via anatomical structures
(shown in blue) are examples of the vocabularies used in the assertions.assertions stating a relationship between AD and various
Pathological Observations included ‘AFFECTS’, ‘CAUSES’,
‘HAS FEATURE’, ‘LEADS TO’, ‘RESULTS IN’. For asser-
tions between Anatomical Structure and Protein/mRNA,
relationships such as EXPRESSES, HAS CONSTITU-
ENT, IS LOCATION OF, IS SITE OF ALTERATION
OF, HAS UPREGULATED were used. For assertions be-
tween Protein/mRNA and AD, relationships such as IS
AFFECTED IN, IS EXPRESSED IN, IS ALTERED IN, IS
COMPONENT OF, IS HIGHER IN, IS INCREASED IN,
IS RISK FACTOR FOR, IS LOCATED IN were used.
To support the assertion generation process, a range of
publicly accessible information sources were identified.
These are detailed in Table 2 and included textual
sources, such as full-text literature review papers, Med-
line abstracts, and reports from a variety of web-based
AD research forums, as well as structured databases,
such as gene expression databases (NCBI GEO), protein-
pathway databases (e.g. GO, KEGG) and protein-disease
association databases (e.g. OMIM). All sources provided
both vocabularies and relevant assertions. The assertion
generation process used the Sofia platform (see http://
www.biowisdom.com/tag/sofia/ and [10]) and was pow-
ered by the broad vocabularies around Proteins, Obser-
vations and Tissues, to enable semantic consistency of all
final assertions. All the data sources were accessed
between July 2006 and October 2006.
For unstructured data sources such as Medline, both
lexical (pattern-matching) and linguistic (part-of-speech
identification) techniques were used to extract relation-
ships that exist between any of the Concepts in the net-
work map. Several repeat extraction methods were
applied, each using a different pattern of noun phrase,
thus allowing for the diversity of language patterns used.
The result was a high level of recall. The extraction pro-
cedure yielded a set of “proto-assertions”, composed ofIntelligence Network relevant for the discovery of candidate
NAs and AD (and sub-types), or indirect links via gene mutations (e.g.
ocesses (e.g. neuronal degeneration, amyloid formation, neurofibrillary
(e.g. hippocampus, CA3 region, thalamus, temporal lobe). The relations
Table 1 Sample vocabularies for key AD disease, pathological observations, and tissue concepts, used in the AD IN
Alzheimer's Disease sub-types Pathological observations in AD Brain regions affected in AD
Alzheimer's Disease Acute-Phase Reaction Amygdala
Early Onset Alzheimer's Disease Amyloid Deposition Anterior Thalamic Nucleus
Early Onset Familial Alzheimer's Disease Amyloid Fibril Formation Basal Nucleus of Meynert
Familial Alzheimer's Disease Amyloidosis CA1 region
Incipient Alzheimer's Disease Asymmetric Cortical Atrophy CA2 region
Late Onset Alzheimer's Disease Blood Brain Barrier Dysfunction CA3 region
Late Onset Sporadic Alzheimer's Disease Central Nervous System Inflammation Cholinergic Neuron
Mid-Stage Alzheimer's Disease Cerebral Atrophy Diagonal Band of Broca
Mild-to-Moderate Alzheimer's Disease Cholinergic Dysfunction Entorhinal Cortex
Moderate Alzheimer's Disease Corpus Callosum Atrophy Frontal Lobe
Moderate-to-Severe Alzheimer's Disease Dystrophic Neuronal Growth Hippocampus
Sporadic Alzheimer's Disease Glial Inflammation Inferior Temporal Gyrus
Severe Alzheimer's Disease Gliosis Left Thalamus
Glucose Hypometabolism Locus Coeruleus
Granulovacuolar Degeneration Medial Temporal Cortex
Hippocampal Neurodegeneration Parahippocampal Gyrus
Inflammation Parietal Lobe
Locus Coeruleus Neuronal Loss Prefrontal Cortex
Mitochondrial Failure Septal Nucleus
Nerve Degeneration Subiculum
Neuritic Plaque Formation Substantia Innominata
Neurofibrillary Degeneration Superior Temporal Gyrus
Neurofibrillary Lesion Synapse
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Table 2 Data sources used for the generation of the Intelligence Network
Databases Description
Alzheimer Disease & Frontotemporal Dementia Mutation Database
(http://www.molgen.ua.ac.be/ADMutations/Default.cfm)
The Alzheimer Disease & Frontotemporal Dementia Mutation Database
(AD&FTDMDB) aims at collecting all known mutations and non-pathogenic
coding variations in the genes related to Alzheimer disease (AD) and
frontotemporal dementia (FTD). All data were exported and loaded into Sofia, to
create gene-disease assertions.
Diseases Database (www.diseasesdatabase.com) The Diseases database is a cross-referenced medical dictionary of diseases,
medications, symptoms, signs and investigations, which was loaded into Sofia
and provided assertions linking Alzheimers disease to symptoms and signs,
histopathological abnormalities, risk factors etc.
Gene Ontology (www.geneontology.org) The Gene Ontology project provides an ontology of defined terms representing
gene product properties. The ontology covers three domains for the gene
products: cellular component, molecular function, & biological process. All of GO
was processed and loaded into Sofia, and the relevant assertions were then
exported into the IN.
Genetic Association Database (http://geneticassociationdb.nih.gov) The Genetic Association Database is an archive of human genetic association
studies of complex diseases and disorders. All the data linking genes to diseases
were processed and downloaded into Sofia, and the relevant assertions were
then exported into the IN.
Gensat Brain Atlas (www.gensat.org) GENSAT is a gene expression atlas of the developing and adult central nervous
system of the mouse. After AD-related brain areas were identified from literature
reviews, the relevant genes were exported from GENSAT, and assertions linking
gene to anatomical area created and loaded into Sofia.
KEGG (www.genome.jp/kegg/pathway.html) KEGG (Kyoto Encyclopedia of Genes and Genomes) is a bioinformatics resource
for linking genomes to life and the environment. Pathways relevant to AD were
reviewed, and relevant protein-pathway assertions were generated using Sofia.
NCBI Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo) Gene Expression Omnibus (GEO) is a database repository of high throughput
gene expression data and hybridization arrays, chips, microarrays. GEO was
searched for AD-relevant expression data, which were downloaded from the
NCBI site and loaded into Sofia.
OMIM (http://www.omim.org/) Online Mendelian Inheritance in Man (OMIM) is a database that catalogues all
the known diseases with a genetic component, and if possible, links them to the
relevant genes in the human genome and provides references for further
research and tools for genomic analysis of a catalogued gene. All of OMIM
Genemap was exported and loaded into Sofia; relevant AD records were used to
create gene-disease assertions.
Telemakus knowledgebase (http://www.telemakus.net/AD/) Telemakus Biomarkers in Alzheimer's Disease & Mild Cognitive Impairment
Knowledgebase contains information from AD and MCI biomarker studies. All of
the Knowledgebase was exported and loaded into Sofia as protein-disease
assertions.
Textual Data Description
PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) PubMed is a service of the U.S. National Library of Medicine that includes over
18 million citations from MEDLINE and other life science journals for biomedical
articles back to the 1950s. PubMed contains a rich set of biomedical literature
abstracts relevant to many areas. AD-relevant vocabularies within Sofia were
used to build a "corpus" of AD-relevant abstracts, which were then used in
assertion-generation processes to create disease-protein and disease-process
links.
Full text papers and reports Various full text reviews from journals, and reports from AD websites (Alzheimer
Research Forum; http://www.alzforum.org/ and Essential Science Indicators;
http://www.esi-topics.com/alzheimer/) were downloaded, and text versions were
loaded into Sofia for assertion generation using key AD-related vocabularies.
Greco et al. Journal of Translational Medicine 2012, 10:217 Page 5 of 10
http://www.translational-medicine.com/content/10/1/217subject-verb-object triplets. All proto-assertions were
manually checked by trained curators, to ensure that the
each component of the triplets had matched appropri-
ately and the assertion was represented accurately in the
underlying reference. Inappropriate assertions were dis-
carded. Each curator was able to validate approximately
500 assertions per day. An accuracy level of greater than97% was confirmed by random sampling and quality
control testing (following an ISO 2859 sampling scheme).
For structured sources, generally the whole data source
was downloaded and parsed into Sofia with the appropri-
ate relationships, and accuracy levels were checked
within an appropriate sample set. Overall, the design-
build-curate-QC process for the IN took a total of three
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tions, linking more than 200 different pathological obser-
vation concepts, over 6,500 protein concepts, and over
35 anatomical/tissue concepts.
Derivation of candidates from intelligence network
The use of the resulting IN, which essentially repre-
sented a semantically-consistent layer over previously
disparate information sources, provided an opportunity
to apply simple filtering techniques that in this case led
to the derivation of a set of proteins fitting the criteria
for a candidate biomarker for AD. According the work-
flow in Figure 2, the IN was first searched for proteins
expressed in brain regions of relevance to AD. This set
of proteins was then filtered further, retaining only those
with assertional evidence for upregulation in AD. Of
those proteins, only those that report assertions high-
lighting an involvement in the development of the
pathological hallmarks of AD were retained. The pro-
teins identified as potential biomarkers by this in silico
approach were then subjected to an assessment of nov-
elty to see whether relevant publications that discussed
the possible use of the biomarkers for AD existed.
In vitro assessment of candidate biomarkers
Samples
In order to validate candidate proteins identified in the
in silico study we utilized samples from the multisite
European AddNeuroMed cohort [11]. A total of 300Figure 2 In silico workflow to identify candidate AD
biomarkers. The workflow shows the steps used to filter the
proteins to a set of potential AD biomarkers. For each step, the
number of proteins identified is shown in red.samples with imaging and clinical data available includ-
ing 100 each of AD cases, normal elderly controls, and
MCI cases and collected from 6 locations across Europe
(Kuopio, Finland; London, United Kingdom; Perugia,
Italy; Toulouse, France; Lodz, Poland; and Thessaloniki,
Greece) were used with all biochemistry assessments
being blind to disease status. The AddNeuroMed study
including diagnostic process, data and sample collection
and curation protocols and imaging processes are
described elsewhere [11-13].
Imaging
The imaging protocols and analysis of MRI within
AddNeuroMed is described elsewhere as noted above. In
brief, MR images are subjected to automated analysis
following parcellation of the brain in a pipeline that
results in over 70 regional cortical volumes and thick-
ness of grey matter variables. Correlational and other
analysis of these variables have shown similar diagnostic
and predictive qualities as in other, comparable studies
such as ADNI [14,15]. Variables that contribute most to
diagnostic accuracy include, unsurprisingly those reflect-
ing atrophy in areas of brain known to be most affected
by AD including entorhinal cortex and hippocampus.
Protein quantization in plasma
We performed semi-quantitative immmunoblotting of
diluted (1:50) plasma for two candidate proteins as a val-
idity test process for the in silico study. The immuno-
blotting protocol has been previously described [7] but
in brief involved separation by SDS-PAGE, transfer to
nitrocellulose, incubation with primary antibody and
identification with secondary antibody. Antibodies used
in this study included those for ChAt, mouse monoclo-
nal anti-human ChAt antibody (Chemicon Clone 1.
B3.9B3) and for PLAUR mouse monoclonal anti-human
PLAUR antibody (R&D, CD87, cat.no. MAB807).
Blots were then scanned with Odyssey Infrared Im-
aging (Li-Cor Bioscience) scanner and analyzed using
Odyssey Infrared Imaging System Version 1.2. The Inte-
grated Intensity for each band of the relevant molecular
weight was determined and background subtracted.
Statistical analysis
The Integrated Intensity value for both ChAt and
PLAUR, corrected for protein loading was analyzed
using SPSS (v19). Following tests to assess the normality
of data distribution (Kolmogorov-Smirnov and Shapiro-
Wilk), we first used ANOVA to determine the relation-
ship between protein level and case status and then per-
formed bivariate correlation (Spearman rank correlation)
between protein values and brain atrophy measured
using MRI.
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In silico discovery of candidate biomarkers
In order to identify potential peripheral AD biomarkers
we first performed a consensus building exercise which
suggested that an AD biomarker might have the charac-
teristics of being a protein expressed in areas of the brain
known to be affected by AD and to be associated with a
pathological process relevant to AD and to be differen-
tially expressed in AD. We then utilized text mining and
linguistics analysis to construct the ‘AD Biomarker
Intelligence Network’ from meta-assertional data derived
from all major publically available biological datasets. The
workflow described in Figure 2 revealed the following:
 5,257 proteins and/or mRNAs expressed in AD
tissue
 of these, 67 reported evidence for upregulation in




Amyloid beta (A4) precursor protein (protease nexin-II,




B-cell leukemia/lymphoma 2 BCL2
Beta-site APP-Cleaving Enzyme 1 BACE1
Butyrylcholinesterase BCHE
C-reactive protein, pentraxin-related CRP
Choline Acetyltransferase CHAT
Clusterin CLU
Complement component 1, q subcomponent, beta polypeptide C1QB
Estrogen Receptor 1 (alpha) ESR1
Glial fibrillary acidic protein GFAP
Heat shock 70kD protein 5 (glucose-regulated protein) HSPA5
Interleukin 1 beta IL1B
Interleukin 6 IL6
Matrix Metallopeptidase 9 MMP9
Nerve Growth Factor NGF
Nitric Oxide Synthase 2A NOS2
PRKC, apoptosis, WT1, regulator PAWR
Prostaglandin-Endoperoxide Synthase 2 PTGS2
Transforming Growth Factor, Beta 1 TGFB1
Transthyretin TTR
Tumor Necrosis Factor (TNF superfamily, member 2) TNF
Urokinase Plasminogen Activator Receptor PLAUR of these, 25 have known associations with a
pathological process in AD
These candidate biomarker proteins are listed in
Table 3.
In vitro assessment of candidate biomarkers
In order to validate the in silico approach to potential
biomarker discovery, we chose two proteins not previ-
ously suggested as peripheral biomarkers for AD –
PLAUR and ChAt – and determined the levels of these
proteins in plasma from 240 subjects from the
AddNeuroMed cohort, a European AD biomarkers
study, using semi-quantitative immunoblotting. Only
two proteins not previously associated with AD were
tested and these two were chosen partly as one (PLAUR)
is a known plasma protein altered in other disease states




3 serpin peptidase inhibitor clade A, AACT, ACT
AD1 (Alzheimer disease), ABETA (amyloid beta A4 protein)




CLG4B (92 kDa gelatinase, 92 kDa type IV collagenase)
NGFB
NOS2A, INOS (Inducible NOS), HEP-NOS (Hepatocyte NOS)
PAR4 (Prostate apoptosis response 4 protein)
PGHS2, COX2 (Cyclooxygenase 2b)
TNFA, TNF-alfa
uPAR
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our knowledge and partly for serendipitous reasons -
antibodies suitable for assay generation were readily
available. We aimed first to compare protein levels in re-
search participants with AD, with MCI and normal eld-
erly controls. In addition, as AD has a long prodromal
phase and as a consequence many apparently normal
elderly people have substantial but occult AD pathology,
we also correlated protein levels with cerebral atrophy
measured using automated analysis of structural MRI
(191 subjects with imaging data) as a quantitative mar-
ker of pathological load independent of clinical disease
status.
Table 4 shows the diagnostic category, age and gender
characteristics of the subjects analyzed together with the
results of PLAUR and ChAt analysis. We found PLAUR
to be highly significantly different across categories with
lowest levels in AD, highest in controls and an inter-
mediate level in MCI (ANOVA, p < 0.001). There was no
difference in ChAT comparing the three diagnostic cat-
egories. To estimate degree of pathology regardless of
diagnostic category we used whole brain volume as a
measure of atrophy, derived using automated analysis of
structural MRI as previously reported [12,14,15]. For
PLAUR we found a very highly significant inverse correl-
ation between whole brain volume and protein levels in
plasma. Interestingly the AD group showed a similar dir-
ection of effect although this was not significant. For
ChAt we also found a highly significant, but in this case
positive, correlation between whole brain volume and
plasma protein levels in control subjects with again the
AD group showing a trend towards the same direction
of correlation. In neither case was there any correlation
in the MCI group.
Discussion
The discovery of biomarkers for AD is an increasingly
important task – both for early diagnosis and for use in
experimental medicine. However, it is a task complicated
by at least three major intrinsic difficulties. First the
complexity of AD pathology means that identification of
candidate markers, beyond the low hanging fruit of AβTable 4 Subject characteristics and PLAUR and ChAt analysis
N Gender (% F) Age mean (SD) MMSE* mean (SD) PLAU
Controls 82 58 72.8 (7.0) 29 (1.1)
MCI 80 57 74.7 (6.2) 27 (2.2)
AD 78 69 76.2 (6.4) 21 (4.5)
*MMSE; Mini mental state examination - a cognitive scale (maximum score = 30) us
24 indicates possible dementia. A score of 10–20 suggests moderate dementia andand tau, is problematical. Second, collection of the opti-
mal peripheral fluid for biomarker identification, CSF, is
relatively invasive and unsuitable for repeated measures
in elderly people. Third, AD has a prolonged prodrome
when apparently normal elderly people harbor consider-
able pathological load meaning that the conventional
case–control design is confounded by pathology in clin-
ically unaffected subjects. Previously we and others have
attempted to mitigate the third of these complications
by using a design of biomarker discovery where the in-
dependent or outcome variable is not clinical diagnosis
but an endophenotype of disease such as structural MRI
evidence of atrophy [7] or PET evidence of Aβ load [6].
The second of the limitations in biomarkers for AD –
the availability of CSF – has prompted many groups to
seek markers in other fluids such as plasma. The first of
the limitations, the identification of candidates, has been
previously attempted by two broad categories of studies;
either using candidates based on the researcher’s own
understanding of disease or using a data-driven, most
often proteomic, approach. Here we combine the use of
endophenotypes to complement diagnostic category as
an outcome measure, with the use of plasma as a bio-
marker tissue, with an entirely novel approach to the
identification of candidates. This innovation makes use
of linguistic and textual analysis to interrogate the entire
biomedical knowledge base in the form of all the major
publicly available databases to identify candidate markers
using a consensus driven set of primary assertions. We
accessed the various data sources in 2006, and clearly in
a fast moving field data will have changed considerably
in the intervening years. Indeed some of the proteins
identified in 2006 (such as Transthyretin and Clusterin)
had not at that time been considered as biomarkers.
However, when the in vitro analysis was carried out, data
had been provided from our own proteomics studies
that these proteins were in fact putative biomarkers.
Thus this time lag has inadvertently provided further
substantiation of the proof of concept of the in silico ap-
proach that we discuss here.
The textual analysis of publicly available data sources









R mean (SD) ** R p ChAt mean (SD) ** R p
1.63 (0.9) −0.35 <0.005 0.78 (0.3) 0.34 <0.01
0.98 (0.7) 0.14 NS 0.75 (0.3) 0.01 NS
0.85 (0.3) −0.2 NS 0.71 (0.3) 0.23 0.06
ed to screen for and assess degree of severity of dementia. A score of less than
a score above 20, mild dementia. ** arbitrary units.
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tial biomarkers in plasma. For example, using MRI mea-
sures of atrophy as an outcome endophenotype we
identified and confirmed plasma Clusterin [7] and Trans-
thyretin [16] as measure of severity of disease and using
PET measures of amyloid identified apoE protein as the
primary correlate in plasma [6]. All these studies used
gel based proteomics as the discovery tool and the fact
that textual analysis identifies the same proteins before
these proteomic studies were performed is a strong indi-
cator of the power of the method. Other promising can-
didates suggested by textual analysis, and where there is
published data suggesting that these proteins are altered
either in blood or CSF, include CRP [17-19], Comple-
ment factor 1 [20,21], butyrylcholinesterase [22] and
BACE1 [23,24]. In all but the case of butyrylcholinester-
ase, this biomarker data was published after the IN lock-
down and hence these biomarker utility data are inde-
pendent of the IN and act as independent proof of
concept.
As the IN identified as potential protein biomarkers
proteins previously identified in proteomic studies –
without this data entering into this particular network –
we were encouraged to attempt further validation in
plasma. We chose two proteins - neither previously
identified as potential plasma biomarkers to our know-
ledge - and measured these in over 200 subjects most of
whom had as part of the European AddNeuroMed pro-
ject, automated analysis of structural MRI data available.
One of these proteins – PLAUR – was significantly
decreased in AD relative to controls with MCI being at
an intermediate level. Both PLAUR and ChAT showed a
correlation, inverse in the case of PLAUR, with imaging
evidence of atrophy in control cases and both showed a
smaller and non-significant, but in the same direction,
correlation in AD cases. We used semi-quantitative im-
munoblotting as a screening method as in previous stud-
ies as this approach, in contrast to ELISA for example,
yields information on degradation products and post
translational modifications. In fact the data on these two
chosen proteins suggested whole protein correlation
with disease state suggesting future biomarker replica-
tion and qualification studies, beyond the intention of
the present investigation, might progress rapidly to fully
quantitative methods.
Urokinase plasminogen activator receptor (PLAUR) is
a protein involved in many biological functions including
cell signaling [25,26]. By binding urokinase plasminogen
activator (uPA), with which it forms an active complex
(uPA-PLAUR), it catalyzes the transformation of zymo-
gen plasminogen into the active protein plasmin, a
serine protease which degrades fibrin. The receptor is
also involved in cell signaling and in chemotaxis, and
controls cell adhesion. Increased levels of PLAUR havebeen previously reported in inflammatory disorders [27]
and has been implicated in chemotaxis leading to micro-
glial accumulation in the core of amyloid plaques in
brain in transgenic rodent models of AD. Aβ induces
PLAUR [28] and PLAUR is increased in microglia cells
of human AD brains and in brains treated with amyloid
β peptide [29,30]. The inverse relationship we observe
between soluble PLAUR and AD and brain atrophy is
noteworthy and might suggest an inverse relationship ei-
ther between soluble and, functional, membrane bound
PLAUR or between central and peripheral PLAUR more
generally. An inverse relationship between central amyl-
oid load and peripheral, CSF, amyloid has been previ-
ously and extensively noted. The other novel protein
association with pathology we identify, ChAt, is a key
component of the cholinergic pathway which is severely
affected in AD and is the target for the first symptomatic
therapies for AD. We observe a relationship between
cerebral atrophy and ChAT protein and this may reflect
the loss of cholinergic neurons known to occur early in
disease process.
In summary we show here that the extraction of data
from huge volumes of biological datasets including text
based information is possible and that the creation of
hypothesis or assertion-driven analysis yields potential
biomarkers. As some of these markers have been inde-
pendently generated using proteomics, and, as here we
show at least partial validation of the two markers tested,
this finding offers strong support to a text mining ap-
proach to biomarker discovery using the ever increasing
publically available datasets.
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